PRAME and medulloblastoma: Subsequently, numerous studies reported that overexpression of PRAME was significantly correlated with clinicopathological features in malignant cancers, including medulloblastoma (Orlando et al., 2018), lung adenocarcinoma (Pan et al., 2017), uveal melanoma (Gezgin et al., 2017), high-grade serous cancer (Zhang et al., 2016), myxoid liposarcoma (Iura et al., 2015), osteosarcoma (Tan et al., 2012), bladder cancer (Dyrskjot et al., 2012), breast carcinoma (Epping et al., 2008), and solitary fibrous tumors (Wang et al., 2021).